<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328808</url>
  </required_header>
  <id_info>
    <org_study_id>4839 - APAP</org_study_id>
    <nct_id>NCT01328808</nct_id>
  </id_info>
  <brief_title>Metabolism and Toxicity of Acetaminophen</brief_title>
  <official_title>Metabolism and Toxicity of Acetaminophen in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John van den Anker</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's National Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate how acetaminophen (APAP) is released into the
      urine and blood; to determine how the blood levels of acetaminophen and its breakdown
      products affect the preterm infant's health; to decrease adverse drug reactions; and to
      collect data on how the genetic make-up or characteristics affect how APAP is handled within
      the preterm infant. By taking several blood and urine samples during the study, we will be
      able to check the blood levels (called pharmacokinetics) of APAP in preterm babies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study procedures: The decision to replace standard intravenous morphine therapy with APAP
      will be made by the attending neonatologist.

      Length of participation: 60 hours. No patient will be prescribed the medication specifically
      for the study purposes in the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary endpoint PK analysis</measure>
    <time_frame>48 hours</time_frame>
    <description>Blood and urine levels of APAP and metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Developmental stage</measure>
    <time_frame>48 hours</time_frame>
    <description>To assess both the magnitude and statistical significance of any evidence of relationship between developmental stage and toxicity-associated metabolite levels.
The analyses will also hold constant APAP dose, BID or TID and possible confounding variables such as birth order, maternal smoking status, and maternal age. We will plot the relationship between stage of development and measures of APAP Metabolism, taken at different gestational and postnatal ages. A hierarchical, cross sectional time series models will be used.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>group 2 Pain management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.
In preterm and term neonates with a GA of less than 28 weeks 15 mg/kg dose of APAP will be given every 12 hrs by an intravenous infusion over 30-minute</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen/APAP</intervention_name>
    <description>In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.
In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute</description>
    <arm_group_label>group 2 Pain management</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm and term neonates of both genders and all races

          -  a postnatal age of less than 28 days

          -  GA's of from 22 to less than 37 weeks

          -  an indwelling (peripheral or umbilical) arterial line

          -  a clinical indication for intravenous administration of pain relief medication

        Exclusion Criteria:

          -  Neonates with severe asphyxia

          -  grade III or IV intraventricular hemorrhage, major congenital malformations/facial
             malformations (e.g., cleft lip and palate),

          -  neurological disorders

          -  those receiving continuous or intermittent neuromuscular blockers

          -  clinical or biochemical evidence of hepatic renal failure (including systemic
             hypoperfusion)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Weeks</minimum_age>
    <maximum_age>37 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John N van den Anker, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's National Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N, Williams EF, Wilkins DG, Sherwin CM, van den Anker JN. Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model. Clin Pharmacokinet. 2016 Nov;55(11):1395-1411.</citation>
    <PMID>27209292</PMID>
  </results_reference>
  <results_reference>
    <citation>Cook SF, King AD, van den Anker JN, Wilkins DG. Simultaneous quantification of acetaminophen and five acetaminophen metabolites in human plasma and urine by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: Method validation and application to a neonatal pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Dec 15;1007:30-42. doi: 10.1016/j.jchromb.2015.10.013. Epub 2015 Oct 31.</citation>
    <PMID>26571452</PMID>
  </results_reference>
  <results_reference>
    <citation>Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker JN. Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation. Clin Pharmacokinet. 2016 Jan;55(1):107-19. doi: 10.1007/s40262-015-0301-3.</citation>
    <PMID>26201306</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 30, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2011</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's National Research Institute</investigator_affiliation>
    <investigator_full_name>John van den Anker</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Preterm Infants</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data. Preliminary data published Published manuscripts in 2015 &amp; 2016</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

